Drug Trial Radar · NCT07946848
Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
May 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- Immuneering CorporationIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non-Squamous Non Small Cell Lung Cancer
- Metastatic Non-Small Lung Cell Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Lung Cancer (NSCLC)
Interventions
AtebimetinibDrug
Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg
CemiplimabBiological
Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks
CarboplatinDrug
AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4
Pemetrexed (500 mg/m²)Drug
500 mg/m² IV on Day 1 of Cycles 1-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of AtebimetinibTime frame: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
- Objective Response Rate (ORR)Time frame: Every 8 weeks, up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Virginia Cancer Specialists, PC
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.